S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Why Your IRA Could Crash on January 16th? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Why Your IRA Could Crash on January 16th? (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
Why Your IRA Could Crash on January 16th? (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Why Your IRA Could Crash on January 16th? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Why Your IRA Could Crash on January 16th? (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
Why Your IRA Could Crash on January 16th? (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Why Your IRA Could Crash on January 16th? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Why Your IRA Could Crash on January 16th? (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
Why Your IRA Could Crash on January 16th? (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Why Your IRA Could Crash on January 16th? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Why Your IRA Could Crash on January 16th? (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
Why Your IRA Could Crash on January 16th? (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
NASDAQ:CYCC

Cyclacel Pharmaceuticals - CYCC Stock Forecast, Price & News

$0.68
-0.05 (-6.84%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.66
$0.75
50-Day Range
$0.68
$1.46
52-Week Range
$0.66
$4.53
Volume
101,073 shs
Average Volume
412,681 shs
Market Capitalization
$8.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CYCC stock logo

About Cyclacel Pharmaceuticals (NASDAQ:CYCC) Stock

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.

Receive CYCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CYCC Stock News Headlines

Cyclacel Pharmaceuticals (NASDAQ: CYCC)
Cyclacel Pharmaceuticals's Earnings Outlook
Cyclacel Pharmaceuticals Q4 2021 Earnings Preview
Cyclacel Pharmaceuticals, Inc. (CYCC)
See More Headlines
Receive CYCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CYCC Company Calendar

Last Earnings
11/10/2021
Today
12/07/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/27/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CYCC
Employees
2,018
Year Founded
N/A

Profitability

Net Income
$-18,890,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.73 per share

Miscellaneous

Free Float
12,012,000
Market Cap
$8.54 million
Optionable
Not Optionable
Beta
1.01

Key Executives

  • Mr. Spiro George RombotisMr. Spiro George Rombotis (Age 63)
    Pres, CEO & Exec. Director
    Comp: $839.53k
  • Mr. Paul McBarron (Age 61)
    Exec. VP of Fin., CFO, COO, Sec. & Exec. Director
    Comp: $444.86k
  • Dr. Mark H. Kirschbaum M.D. (Age 61)
    Sr. VP & Chief Medical Officer
    Comp: $531.58k
  • Ms. Gill Christie (Age 65)
    Director of HR
  • Dr. Robert Westwood Ph.D. (Age 78)
    Head of Preclinical Devel. and VP of Chemistry & Preclinical Devel.













CYCC Stock - Frequently Asked Questions

Should I buy or sell Cyclacel Pharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CYCC shares.
View CYCC analyst ratings
or view top-rated stocks.

How have CYCC shares performed in 2022?

Cyclacel Pharmaceuticals' stock was trading at $3.89 on January 1st, 2022. Since then, CYCC stock has decreased by 82.5% and is now trading at $0.6813.
View the best growth stocks for 2022 here
.

When is Cyclacel Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our CYCC earnings forecast
.

How were Cyclacel Pharmaceuticals' earnings last quarter?

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) announced its quarterly earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.70) by $0.16. During the same quarter last year, the company earned ($0.47) earnings per share.

When did Cyclacel Pharmaceuticals' stock split?

Cyclacel Pharmaceuticals's stock reverse split on Wednesday, April 15th 2020. The 1-20 reverse split was announced on Tuesday, April 14th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 14th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Spiro Rombotis' approval rating as Cyclacel Pharmaceuticals' CEO?

1 employees have rated Cyclacel Pharmaceuticals Chief Executive Officer Spiro Rombotis on Glassdoor.com. Spiro Rombotis has an approval rating of 100% among the company's employees. This puts Spiro Rombotis in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cyclacel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclacel Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Heat Biologics (HTBX), McEwen Mining (MUX) and Tesla (TSLA).

What is Cyclacel Pharmaceuticals' stock symbol?

Cyclacel Pharmaceuticals trades on the NASDAQ under the ticker symbol "CYCC."

Who are Cyclacel Pharmaceuticals' major shareholders?

Cyclacel Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (1.37%), Renaissance Technologies LLC (1.34%), Two Sigma Investments LP (0.54%), McIlrath & Eck LLC (0.21%), Kestra Advisory Services LLC (0.18%) and Raymond James Financial Services Advisors Inc. (0.17%). Insiders that own company stock include Sam L Barker and Spiro George Rombotis.
View institutional ownership trends
.

How do I buy shares of Cyclacel Pharmaceuticals?

Shares of CYCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cyclacel Pharmaceuticals' stock price today?

One share of CYCC stock can currently be purchased for approximately $0.68.

How much money does Cyclacel Pharmaceuticals make?

Cyclacel Pharmaceuticals (NASDAQ:CYCC) has a market capitalization of $8.54 million. The biotechnology company earns $-18,890,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis.

How many employees does Cyclacel Pharmaceuticals have?

The company employs 2,018 workers across the globe.

How can I contact Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals' mailing address is 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922. The official website for the company is www.cyclacel.com. The biotechnology company can be reached via phone at (908) 517-7330, via email at ir@cyclacel.com, or via fax at 866-271-3466.

This page (NASDAQ:CYCC) was last updated on 12/8/2022 by MarketBeat.com Staff